Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Octant Inc. operates within the Biotechnology & Pharmaceuticals technology area. The company currently manages 1 pending office action. This single action is assigned to 1 distinct examiner and is located within 1 distinct art unit. Such a concentrated portfolio suggests a specific focus for the company's current patenting activities in the biotechnology sector.
The busiest examiner identified in the data is PAK, MICHAEL D. This examiner is responsible for 1 pending office action. As this is the only pending action for the company, the entire prosecution strategy is currently centered on the feedback and requirements of this specific individual. This creates a singular path for the company's active application.
The alignment of 1 pending office action with 1 distinct art unit indicates that there is no variation in the technical classification of the company's current workload. Practitioners should note that the prosecution experience is currently limited to this single point of engagement. This environment allows for a focused approach to addressing the examiner's concerns within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.3% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275199 | SYSTEMS AND METHODS FOR MEASURING CELL SIGNALING PROTEIN ACTIVITY | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275199 | SYSTEMS AND METHODS FOR MEASURING CELL SIGNALING PROTEIN ACTIVITY | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275199 | SYSTEMS AND METHODS FOR MEASURING CELL SIGNALING PROTEIN ACTIVITY | PAK, MICHAEL D | 1644 | §101§102§112Other | Non-Final OA | — | Pending | Jul 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial